ArticleGlobal & regional health technology assessment
The societal costs associated with patients with chronic spontaneous urticaria (CSU) in Italy.
Article in Global & regional health technology assessment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic spontaneous urticaria (CSU) is a debilitating dermatological disease. The study aimed to estimate the indirect costs and out-of-pocket expenses incurred by CSU patients in Italy. Methods: The economic model was based on data collected through a survey conducted among patients and caregivers with the support of the Association for the Research and Cure of Urticaria (ARCO). Disease severity was classified into three categories: mild, moderate and severe. Indirect costs were estimated using the human capital approach. Out-of-pocket expenses were estimated in terms of direct healthcare costs borne by the patient and direct non-healthcare costs. Results: Data were analyzed for 122 patients; 7% of these reported mild CSU, 16% moderate and 78% severe. The average age was 46.8 years, with an average age at diagnosis of 38.2 years. Overall, 50% of employed patients lost workdays due to CSU, and 63.3% reported reduced productivity at work; 45.1% of patients received caregiver support, with 37.9% of employed caregivers reporting workdays lost. The economic model estimated an average annual indirect cost per patient with CSU of €4,281, mainly due to presenteeism (59%). Indirect costs increase with the severity of the disease. Average annual out-of-pocket expenses was €502.7 per patient. Conclusions: The study conducted based on data directly reported by patients could contribute to a better understanding of CSU, thereby promoting a more efficient approach to the care and support of patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.